Press Release
19 Dec, 2017
On December 19, 2017, ICP-022, an innovative pharmaceutics with wholly-owned intellectual property rights, was approved by the State Food and Drug Administration (CFDA) for clinical trials against systemic lupus erythematosus (SLE) and rheumatoid arthritis. Autoimmune diseases such as SLE and RA are serious threats to human health. More than 2 million Chinese patients still lack effective treatments. ICP-022 is a highly specific BTK inhibitor with excellent efficacy in SLE and RA models. It has shown good tolerance and safety in phase I clinical trial on healthy subjects in Australia. It is expected to provide safe and effective treatment options for patients with SLE and RA. Dr. Jisong Cui, co-founder, chairman and CEO of InnoCare, said: “The clinical trial of ICP-022 has been approved, which means that the first research product from InnoCare, which was established 2 years ago, will soon enter clinical development in China. The reform of domestic pharmaceutical policy and the steady growth of the pharmaceutical market are crucial to the development of InnoCare. We are very happy to receive this approval and look forward to officially launching the clinical research of ICP-022 in mainland China." About ICP-022 ICP-022 is a highly specific BTK inhibitor with excellent kinase selectivity and drug-like properties. Good safety and pharmacokinetic properties have been shown in clinical trials in Australia. It has good prospects for the treatment of autoimmune diseases.
21 Sep, 2016
September 20-21, 2016, Dr. Jasmine Cui, President & CEO of InnoCare Pharma was invited to be the Chair and gave an opening speech at the conference. Bio Partnering APAC 2016 is designed to be a premium collaborative platform for big pharmas, biotechs, investors and other stake holders in pharma industry to meet, communicate and establish partnership on pharma R&D. Bio Partnering APAC 2016 is hosted by Shine Consultant and supported by Sino-American Pharmaceutical Professional Association (SAPA), CBA, Taiwan Bio Industry Organization. Senior executives from pharmaceutical and biopharma companies  including Pfizer, Merck, Novartis, Roche, Sanofi-Aventis, Eli Lilly, Johnson & Johnson and Hutchsion Medi Pharma had intensive discussion on hot topics in Pharma R&D. Experts from investment companies or consulting firms such as McKinsey, Morningside Asia Venture, Lilly Asia Venture Fund also joined the discussion.
03 Jun, 2016
On June 3rd, 2016, Ms. Huang Lixin, a member of Jiangsu Provincial Committee and the secretary of Nanjing municipal committee of the CPC, along with other officials from relevant departments, visited InnoCare Nanjing.   Ms. Huang Lixin looked into details of the company’s new drug research and development, the talented team, the scientific and technological achievements, and other aspects of the company, fully affirmed the development of the company’s achievements. As Ms. Huang pointed out, bio-pharmaceutical product development takes a long time, typically more than a decade for a new drug to reach the market, therefore requiring patience, especially to withstand the “lonely” aspect of the work. She also emphasized that biomedicine is an important focus of Nanjing’s development as an emerging industry. Nanjing’s municipal government fully supports the growth and development of biomedical innovation, and all relevant departments will increase their service efforts towards biomedical enterprises, by actively helping the industry to overcome problems and difficulties that are encountered during its development.
16 May, 2016
On May 16th, 2016, the opening ceremony for InnoCare Nanjing was successfully held in the Nanjing Life Science Park. Officials from the Jiangning District have attended the ceremony and interacted with the InnoCare Nanjing team. InnoCare Nanjing is located in the Nanjing Life Science Park with beautiful scenery. It primarily focuses on the Biology/Medicinal Chemistry and Biomarker development. With opening of the Nanjing site, InnoCare has moved a solid step forward towards the goal of “developing and providing safe and effective innovative medicines to meet the needs of Chinese patients”.